Equities research analysts predict that Beigene Ltd (NASDAQ:BGNE) will announce earnings per share (EPS) of ($1.74) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Beigene’s earnings, with the highest EPS estimate coming in at ($1.41) and the lowest estimate coming in at ($1.94). Beigene reported earnings per share of ($1.05) during the same quarter last year, which would suggest a negative year-over-year growth rate of 65.7%. The company is scheduled to report its next earnings results on Wednesday, March 28th.
According to Zacks, analysts expect that Beigene will report full-year earnings of ($2.04) per share for the current fiscal year, with EPS estimates ranging from ($2.49) to ($1.59). For the next year, analysts expect that the business will report earnings of ($7.56) per share, with EPS estimates ranging from ($9.25) to ($5.88). Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Beigene.
Beigene (NASDAQ:BGNE) last announced its quarterly earnings results on Monday, November 13th. The company reported $2.54 EPS for the quarter, topping the consensus estimate of $0.23 by $2.31. The company had revenue of $220.21 million during the quarter, compared to analysts’ expectations of $1.55 million. During the same quarter in the previous year, the firm earned ($1.08) EPS.
In other news, CMO Amy C. Peterson sold 3,601 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $82.96, for a total transaction of $298,738.96. Following the sale, the chief marketing officer now directly owns 1,201 shares in the company, valued at approximately $99,634.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John Oyler sold 150,957 shares of the stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $80.50, for a total transaction of $12,152,038.50. Following the completion of the sale, the chief executive officer now directly owns 491,891 shares in the company, valued at $39,597,225.50. The disclosure for this sale can be found here. Insiders have sold a total of 483,482 shares of company stock worth $42,139,474 over the last 90 days. Corporate insiders own 19.90% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the stock. Hillhouse Capital Management Ltd. raised its position in Beigene by 172.6% in the 2nd quarter. Hillhouse Capital Management Ltd. now owns 3,720,726 shares of the company’s stock worth $167,433,000 after purchasing an additional 2,355,906 shares during the period. Orbimed Advisors LLC raised its position in Beigene by 2.0% in the 3rd quarter. Orbimed Advisors LLC now owns 1,313,788 shares of the company’s stock worth $135,925,000 after purchasing an additional 26,200 shares during the period. Canada Pension Plan Investment Board purchased a new stake in Beigene in the 3rd quarter worth about $62,076,000. Artal Group S.A. raised its position in Beigene by 10.1% in the 2nd quarter. Artal Group S.A. now owns 400,000 shares of the company’s stock worth $18,000,000 after purchasing an additional 36,714 shares during the period. Finally, Janus Henderson Group PLC purchased a new stake in Beigene in the 3rd quarter worth about $33,744,000. 55.32% of the stock is currently owned by institutional investors.
Shares of Beigene (BGNE) traded up $1.34 during mid-day trading on Friday, reaching $101.67. 220,200 shares of the company’s stock traded hands, compared to its average volume of 189,700. The stock has a market cap of $4,620.00 and a PE ratio of -77.61. Beigene has a 1-year low of $30.67 and a 1-year high of $118.95. The company has a debt-to-equity ratio of 0.20, a quick ratio of 9.27 and a current ratio of 9.33.
Beigene Company Profile
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.